The U.S. Food and Drug Administration (FDA) has granted Priority Review to Rituxan (rituximab) in combination with glucocorticoids for the treatment of children, 2 or older, with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). If Genentech‘s Biologics License Application (sBLA) for Rituxan is approved, this…
News
People who live in the U.S. and have eosinophilic granulomatosis with polyangiitis (EGPA) now can be treated with Nucala (mepolizumab) once every four weeks through at-home injections. The U.S. Food and Drug Administration (FDA) recently approved an autoinjector and a pre-filled safety syringe as new methods to dose…
People with ANCA-associated vasculitis with high levels of myeloperoxidase (MPO) antibodies at diagnosis are more likely to have poor kidney function and lower 2-year renal survival, a study says. The study, “High anti-neutrophil cytoplasmic antibody titers are associated with the requirement of permanent dialysis in patients with myeloperoxidase-ANCA-associated…
ANCA-associated vasculitis patients in Korea have a high prevalence of thyroid dysfunction, with the condition affecting mainly those who are older, have ANCA antibodies, or renal involvement at diagnosis, a study has found. The study, “Thyroid Dysfunction in Patients with Antineutrophil Cytoplasmic Antibody−associated Vasculitis: A Monocentric Retrospective Study,”…
Treatment using plasma exchange can help ANCA-associated vasculitis patients with severe renal damage become independent of dialysis in just a few weeks, according to a study. The study, “Plasma exchange is highly effective for ANCA-associated vasculitis patients with rapidly progressive glomerulonephritis who have advanced to dialysis…
The Birmingham Vasculitis Activity Score (BVAS) and the Five Factors Score (FFS) are both useful tools for predicting the prognosis of ANCA-associated vasculitis, and for selecting the best first-line therapy, a study says. Researchers recommended using both for best patient care. The study, “Comparison of…
News
Rituxan-Soliris Combo May Replace Glucocorticoids in Treatment of Severe AAV, Case Report Suggests
A combination of Rituxan (rituximab) and Soliris (eculizumab) may be used to replace glucocorticoids for the treatment of patients with severe ANCA-associated vasculitis, a case report suggests. The report, “Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and…
The presence of blood in the urine is associated with a four times higher risk of kidney disease relapse within 44 months after achieving remission in patients with ANCA-associated vasculitis, a study has found. The study, “Prognostic Value of Microscopic Hematuria after Induction of Remission in Antineutrophil Cytoplasmic…
RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
Levels of Gremlin — a protein that is overexpressed during kidney damage — in the urine may serve as a specific biomarker for ANCA-associated renal vasculitis, a study shows. The study, “Gremlin, A Potential Urinary Biomarker of Anca-Associated Crescentic Glomerulonephritis,” was published in the journal Scientific Reports.
Recent Posts
- Let’s do away with pity parties and start practicing self-compassion
- Urine protein fragments may help assess kidney inflammation in AAV
- Most AAV patients in North America affected by lung complications
- Sharing what’s on your mind can ease loneliness in life with vasculitis
- Antibody type may influence cardiovascular risk timing in AAV